Innovent Biologics (1801.HK) Earnings Analysis
Innovent Biologics (1801.HK) next reports earnings on 2026-08-26, consensus EPS 1.26 HKD. Last quarter (2026-03-26) it missed with EPS -0.0112 HKD vs 0.1344 HKD est (-108.3%). It has beaten estimates in 2/3 recent quarters (67%). Trailing P/E 157.60.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 1801.HK next report earnings?
| Next earnings date | 2026-08-26 |
|---|---|
| Consensus EPS estimate | 1.26 HKD |
| Revenue estimate | 10.69B |
1801.HK earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-26 | -0.0112 HKD | 0.1344 HKD | -108.3% | Miss |
| 2025-08-26 | 0.555 HKD | 0.1958 HKD | +183.5% | Beat |
| 2024-08-28 | -0.25744 HKD | -0.26816 HKD | +4% | Beat |
Beat rate: 2/3 (67%) over reported quarters with consensus data.
1801.HK valuation and analyst view
| Trailing P/E | 157.60 |
|---|---|
| Trailing EPS | 0.47514 HKD |
| Price / book | 6.94 |
| Dividend yield | 0.00% |
| Market cap | 160.60B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Innovent Biologics (1801.HK)'s next earnings date?
Innovent Biologics is next scheduled to report on 2026-08-26, with a consensus EPS estimate of 1.26 HKD and revenue estimate of 10.69B.
Did 1801.HK beat earnings last quarter?
In its 2026-03-26 report, 1801.HK posted EPS of -0.0112 HKD versus a 0.1344 HKD estimate — a miss of 108.3%.
What is 1801.HK's earnings track record?
Over the last 3 reported quarters with consensus data, 1801.HK beat estimates 2 times (67%).
What is 1801.HK's current P/E ratio and EPS?
1801.HK trades at a trailing P/E of 157.60 on trailing EPS of 0.4751414015735915 HKD.
What do analysts rate 1801.HK?
1801.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.